← CII Learn · Corporate Strategy
Scaling Innovation
Eli Lilly’s 2024 Demand, R&D & Manufacturing Capacity
Analyze how a pharmaceutical company balances rapid product growth, research spending, manufacturing capacity and portfolio risk using Lilly’s 2024 filing. Year ended December 31, 2024; USD millions unless stated. The 2024 Form 10-K and results release were cross-checked. Product revenue and expenses are historical; probability-adjusted pipeline exercises are explicitly hypothetical and are not forecasts.
What you will learn
- Reconcile product growth to consolidated revenue.
- Calculate R&D and capital intensity.
- Separate demand, supply and price effects.
- Distinguish pipeline probability from booked revenue.
- Design a gated capacity decision.